Nothing different. What do you folks want. They are giving an update next week, and one at ASCO. They are moving in the right direction on all fronts. Quit expecting more than has been communicated.
Most don't put news wires out until the conference and the significance is explained. There is massive accumulation, so my view is those in the know are buying all they can. I've bought all I can, broke all my diversification weighting rules. No firm is coming out with a high PT when they are accumulating. $50 is a joke IMHO.
That number is trailing earnings you moron. It's 18.84 times forward earnings which are how companies are valued on discounted flows. The earnings guidance was stellar through 2020, and DIDN'T even include any non-current uses of R, or new drugs or approvals. Since then we have had several new R approvals, new O data, and now Corhn's data. Maybe you should just pay someone to invest for you.
$130, said it's an that they have been working with the FDA and indications must be good.
I posted $300 to $400 PPS based on 1.5 Rev estimate on a drug CEO compared to in Revenues. It seem nuts to post, Then you think about the drug comparison, Soli potential is much broader, and 1.5 times Rev determining market cap, for tech is very low you have some tech Co's selling for 5X-25X Revenue...i.e. Snapchat.
I didn't know anyone gave a rip about their cancer drug; except, now you.
Resuts and data will drive value, not an exchange.
is that with mega dose, no one has dropped out.
This maybe what is driving the price up. For a typical stock, and high level PT analysis by a typical analyst this is what the thinking is:
CEO compared Soli to a 7B-10B $ drug in CC. Let's see, market cap at sales at 1.5X revenue or $15B divide by 37M shares = $405 pps high end, 339 low end. And this is a conservative estimate based on the comparison CEO used against a drug that winding down in use compared to Soli that has a broader application.
CTIX Kevetrin could put them all out of business. Results for PHII due out soon. It regulates P53, which is the holy grail. Some think CTIX's pipeline is world class, antibilotic, skin, etc, cancer. Some think its too good to be true. I know CELG was once interested., a member of the aquisition team thought they may have made a mistake going for A, because if it pans out, Kevetrin,it will put supercede all other cancer drugs for combination therapies. However, t they evaluated it too late, before going another direction
CEO compared Soli to a 7B-10B $ drug in CC. Let's see, sales at 1.5X revenue or $15B divide by 37M shares = $405 pps. What some analyst's use for valuation as a method.
Guess some are scared that the data might not be good??? I think I'll hold for the news. It could really demonstrate why this is the best and most broad application antibiotic, and launch this into space. And then some profit taking is expected.